As per the current market research conducted by the CMI Team, the global Human Microbiome Market size is expected to record a CAGR of 18.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 724.1 Million. By 2033, the valuation is anticipated to reach USD 3,260.5 Million.

Human Microbiome Market: Growth Factors and Dynamics

  • Increasing Awareness and Research: A growing understanding of the role of the human microbiome in health and disease has led to increased research activities and funding. This heightened awareness has propelled the development of novel therapeutics, diagnostics, and other microbiome-based products.
  • Technological Advancements: Advances in sequencing technologies, bioinformatics, and analytical tools have significantly enhanced our ability to study and manipulate the human microbiome. These technological breakthroughs have facilitated deeper insights into microbial communities, leading to the discovery of new therapeutic targets and diagnostic biomarkers.
  • Rising Prevalence of Chronic Diseases: The increasing prevalence of chronic diseases such as gastrointestinal disorders, metabolic diseases, autoimmune diseases, and infections has fueled the demand for microbiome-based interventions. Probiotics, prebiotics, and other microbiome-targeted therapies are being explored as potential treatments or adjunctive therapies for these conditions.
  • Expanding Applications Across Industries: Beyond healthcare, the human microbiome market is expanding into diverse industries such as food and beverages, personal care, and veterinary care. Probiotic-enhanced foods, skincare products targeting the skin microbiome, and microbiome-based animal health products are gaining traction, driving market growth.
  • Regulatory Support and Strategic Collaborations: Regulatory agencies increasingly recognize the human microbiome’s importance and potential applications. Supportive regulatory frameworks and guidelines are facilitating product development and commercialization in the microbiome space.
  • Personalized Medicine and Precision Healthcare: The human microbiome plays a crucial role in personalized medicine and precision healthcare. With advancements in microbiome analysis technologies, healthcare providers can now assess an individual’s microbiome composition and tailor interventions accordingly. This personalized approach holds promise for optimizing treatment outcomes, minimizing adverse effects, and improving patient adherence.

Human Microbiome Market: Partnership and Acquisitions

  • In 2022, PhenoBiome made its human microbiome assay available through Genetic Direction, enabling the performance of assays in its CLIA & CAP-certified laboratory. This collaboration offers access to advanced microbiome testing services, supporting research and clinical applications in microbiome analysis.
  • In 2021, Kaleido Biosciences has partnered with Janssen to explore the potential of microbiome metabolic therapies in preventing childhood-onset immune, atopic, and metabolic conditions. This collaboration aims to leverage microbiome-based interventions to address pediatric health challenges, fostering innovation in preventative healthcare strategies.

Report Scope

Feature of the Report Details
Market Size in 2024 USD 724.1 Million
Projected Market Size in 2033 USD 3,260.5 Million
Market Size in 2023 USD 612.5 Million
CAGR Growth Rate 18.2% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Product Type, Application, Technology, Disease Type and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Human Microbiome Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Human Microbiome Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

  • Disruption in Research and Development: The COVID-19 pandemic has disrupted research and development activities in the human microbiome space due to restrictions on laboratory access, delays in clinical trials, and diversion of resources towards COVID-19-related research. This has slowed down the pace of innovation and product development in the microbiome market.
  • Shift in Healthcare Priorities: Healthcare systems worldwide have been overwhelmed by the COVID-19 crisis, leading to a shift in priorities towards managing and containing the spread of the virus. As a result, attention and resources that were previously allocated to microbiome research and development may have been redirected, impacting funding, investment, and commercialization efforts in the microbiome market.
  • Resumption of Research Activities: With the gradual easing of pandemic-related restrictions and improved safety protocols, research and development activities in the human microbiome field are expected to resume. This includes the continuation of ongoing studies, initiation of new projects, and acceleration of clinical trials for microbiome-based therapeutics and diagnostics.
  • Increased Focus on Immune Health: The COVID-19 pandemic has underscored the importance of immune health in combating infectious diseases. As a result, there is a growing interest in microbiome-based interventions aimed at modulating immune function and enhancing host defense mechanisms. Companies developing probiotics, prebiotics, and other immune-modulating microbiome products may experience increased demand post-pandemic.
  • Telemedicine and Digital Health Solutions: The pandemic has accelerated the adoption of telemedicine and digital health solutions, providing opportunities for remote monitoring and management of microbiome-related conditions. Healthcare providers may increasingly incorporate microbiome testing and consultation into virtual care platforms, enabling broader access to microbiome-based services.
  • Strategic Partnerships and Collaborations: To expedite recovery and stimulate growth, companies in the human microbiome market may engage in strategic partnerships, collaborations, and licensing agreements. By leveraging complementary expertise, resources, and networks, stakeholders can drive innovation, expand market reach, and enhance product development capabilities.
  • Government Support and Funding Initiatives: Governments and funding agencies may implement initiatives to support the recovery of the human microbiome market post-pandemic. This could include increased research funding, tax incentives, regulatory reforms, and public-private partnerships aimed at fostering innovation, entrepreneurship, and commercialization in the microbiome space.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Human Microbiome Market, with some challenges and opportunities arising from the pandemic.

Global Human Microbiome Market 2024–2033 (By Million)

List of the prominent players in the Human Microbiome Market:

  • Seres Therapeutics Inc.
  • Second Genome Inc.
  • Rebiotix Inc.
  • Vedanta Biosciences Inc.
  • uBiome Inc.
  • Finch Therapeutics Group Inc.
  • 4D Pharma PLC
  • Microbiome Therapeutics LLC
  • Synlogic Inc.
  • I. du Pont de Nemours and Company (DuPont)
  • Viome Inc.
  • CoreBiome Inc.
  • Assembly Biosciences Inc.
  • Locus Biosciences Inc.
  • Seed Health
  • Others

The Human Microbiome Market is segmented as follows:

By Product Type

  • Probiotics
  • Prebiotics
  • Medical Foods
  • Drugs
  • Diagnostic Tests

By Application

  • Therapeutics
    • Gastrointestinal Disorders
    • Metabolic Diseases
    • Autoimmune Diseases
    • Infections
    • Others
  • Diagnostics
    • Microbiome Profiling
    • Disease Diagnosis
    • Treatment Decision Support
  • Food & Beverages
  • Personal Care
  • Veterinary

By Technology

  • Sequencing Technologies
  • Microarray Technologies
  • PCR (Polymerase Chain Reaction)
  • Metabolomics
  • Others

By Disease Type

  • Obesity
  • Diabetes
  • Autoimmune Disorder
  • Metabolic and Gastrointestinal Disorders
  • Cancer
  • Others

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America


  • Germany
  • France
  • U.K.
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America